Position PaPer on tuberculosis screening in Patients with immune mediated inflammatory diseases candidates for biological theraPy screening and prevention of TB in patients treated with biological therapy, delegates from the Tuberculosis Committee (TC) of the Portuguese Pulmonology Society (SPP), the Rheumatoid Arthritis Study Group (GEAR) of the Portuguese Society of Rheumatology (SPR), the Portuguese Society of Dermatology and Venereology (SPDV) and the Portuguese Society of Gastroenterology (SPG), have revised and updated recommendations that had been previously developed by the GEAR -SPR and by the TC -SPP, first published in 2006 12 and latter updated in 2008 13 .
The main objective of this position paper is to contribute for the reduction of the number of cases of reactivated TB and new TB infections in patients with immune mediated inflammatory diseases who are candidates for treatment with biological therapy in Portugal. An additional objective is to standardize the procedures used to screen and prevent TB in the initial assessment of these patients, preferably at disease onset, before the beginning of any immunosuppressant therapy. recommendAtIons Who should be screened?
ALL PATIENTS WITH IMMUNE MEDIATED

INFLAMMATORY DISEASES CANDIDATES FOR THE USE OF BIOLOGICAL THERAPY SHOULD BE
SCREENED FOR LATENT TB INFECTION (LTBI) PRIOR TO STARTING THERAPY (EVIDENCE LEVEL C)
Patients eligible for anti-TNF therapy have an increased risk of developing TB upon starting this treatment. TB in this setting can present with severe, atypical and life-threatening manifestations. This risk exists not only due to the biological importance of TNF in the initiation and maintenance of the response against Mycobacterium tuberculosis, but also because the underlying diseases (eg. RA) and concomitant treatments (eg. steroid therapy) increase the risk of TB per se [14] [15] [16] [17] [18] . Most of the active TB cases in patients treated with anti-TNF are due to reactivation of LTBI. It is well known that screening for LTBI before starting anti-TNF therapy is effective in preventing reactivation of TB 17 . Therefore, all national guidelines recommend the exclusion of active TB disease and LTBI in patients in whom biological therapy is considered [19] [20] [21] .
When to screen?
PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES SHOULD BE SCREENED FOR TB BEFORE
STARTING BIOLOGIC TREATMENT AND IDEALLY WHEN
THE DISEASE IS DIAGNOSED (EVIDENCE LEVEL C)
Any candidate to biological therapy should be screened for the presence of specific immune response to M. tuberculosis (including TST and IGRA) before starting these drugs and ideally when the immune mediated inflammatory disease is diagnosed, except in patients with mild forms of psoriasis, treated with topical drugs [19] [20] [21] .
It has been shown that certain diseases, such as RA, as well as chronic immunosuppressive therapy, such as corticosteroids (> 15mg/day for more than 2 weeks) increase the risk of TB. In addition, it is also well known that immunosuppressive therapy compromi ses the sensitivity of the TST and IGRA, being this especially true for TST 16, 18, [22] [23] [24] [25] . Therefore, it is highly desirable that the first screen for TB should be done at the mo ment of diagnosis, before any kind of immunosuppressive treatment or phototherapy is started.
WhIch tests should We use?
AFTER EXCLUSION OF ACTIVE TB, LTBI SHOULD BE SCREENED WITH TST AND IGRA (EVIDENCE LEVEL C AND D)
In the light of current knowledge, and in the absence of a gold standard test for LTBI diagnosis 19 , the screening process for LTBI requires a combination of a detailed medical history (which should include ethnicity, country of birth, history of or recent exposure to TB, previous TB and respective treatment, co-morbidities associated with increased risk of TB, professional activities with increased risk of exposure to TB), travel to endemic areas, chest radiograph (searching for changes indicative of active or residual previous TB) and tests for immunological memory against M. tuberculosis (TST and IGRA) 19 . In erythrodermic psoriasis TST may be impossible to perform, reinforcing the need of IGRA in these cases.
The sensitivity of both tests may be compromised in patients receiving immunosuppressive therapy, although published evidence suggests that IGRA has a higher sensitivity than TST in patients with immune mediated inflammatory diseases, even after starting immunosuppressive therapy [26] [27] [28] [29] [30] .
Currently, different guidelines are adopted regarding the use of TST and IGRA, reflecting the difficulty of choosing the best strategy 19, [31] [32] [33] . Overtreatment, implying the risk of drug toxicity due to a false-positive screening and undertreatment due to a false-negative screening are the main concerns.
duarte r e col.
Since the increase in sensitivity and specificity provided by IGRA in different studies is controversial and their positive and negative predictive values are yet to be defined, the role of IGRA is still under investigation. In this sense, IGRA cannot yet be used as a single test for immunological memory to M. tuberculosis. Thus, currently it is prudent to use both TST and IGRA in order to maximize sensitivity 19, 31, 32 .
Since patients may have false negative TST due to immunossupression, a two step approach is advisedrepeat TST 1-3 weeks after the initial negative screening.
hoW to exclude ActIve tb In pAtIents WIth crohn's dIseAse?
ACID FAST BACILLI SMEAR AND CULTURE SHOULD
BE PERFORMED IN ENDOSCOPIC BIOPSIES (EVIDENCE LEVEL C)
The distinction between Crohn' s disease and intestinal TB is a diagnostic challenge, as they present similar clinical, radiological, endoscopic and histological features.
Investigation of patients with suspected Crohn' s disea se should always include differential diagnosis with intestinal TB. Acid fast bacilli smear and culture are warranted in pathological examination of endoscopic biopsies. Other tests such as nucleic acid amplification, immunohistochemistry or in situ hybridization are promising techniques that have been evaluated in some studies, but they are not widely available and require further validation [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] .
hoW to Interpret the tst?
TST IS CONSIDERED POSITIVE IF INDURATION IS ≥5MM IN PREVIOUSLY IMMUNOSSUPPRESSED PATIENTS AND IF ≥ 10MM IN PATIENTS NOT
PREVIOUSLY EXPOSED TO IMMUNOSSUPPRESSORS (EVIDENCE LEVEL D)
In order to increase the sensitivity of TST (at the expense of lower specificity) different guidelines recommend, in the immunocompromised population, an induration of ³ 5 mm to be the cut-off for a positive TST 19, 21, 53, 54 .
The Tuberculosis Network European Trials Group (TBNET) recommends a cut-off value of 10 mm, stating that the loss of sensitivity to detect infection by increasing the cut-off from 5 to 10mm is marginal, while the gain in specificity is substantial 19 . Taking this into consideration, TBNET suggests that a TST ³ 10mm should lead to LTBI treatment, without re-quiring IGRA confirmation. This evidence is based on results of non-controlled and non randomized trials and on observational studies.
According to the Portuguese clinical practice, patients with immune mediated inflammatory diseases, who are candidates for anti-TNF therapy, should undergo a TST: the test is considered positive in previously immunossuppressed patients if the induration is ≥5mm and in patients not previously exposed to immunossuppressors if the induration is ≥ 10mm.
Who should stArt ltbI treAtment?
PATIENTS WITH EPIDEMIOLOGICAL RISK FACTORS FOR TB (HISTORY OF EXPOSURE TO TB, PREVIOUS TB, EMIGRANTS FROM HIGH TB PREVALENCE
AREAS, RESIDENTS IN HIGH INCIDENCE AREAS, CO MORBIDITIES ASSOCIATED WITH INCREASED RISK
OF TB, PROFESSIONAL ACTIVITIES WITH INCREASED RISK OF EXPOSURE TO TB, TRAVEL TO ENDEMIC AREAS), OR CHEST X-RAY SEQUELAE OF UNTREATED PREVIOUS TB, OR POSITIVE TST AND/OR IGRA, SHOULD START LTBI TREATMENT, AFTER EXCLUSION OF ACTIVE TB. (EVIDENCE LEVEL C AND D):
Whenever there is evidence of exposure to TB (regardless the results of the screening and after exclusion of active TB) or LTBI (positive TST and/or IGRA or changes in chest radiograph suggestive of previous untreated TB), after exclusion of active TB, preventive treatment should be offered before initiating biological therapy, as these patients have a high risk of progression to disease 19, 21, 55, 57, 58 .
Due to the risk of serious forms of disease, treatment must be offered to candidates for biological therapy regardless of age and presumed date of infection.
WhIch ltbI treAtment regImen should be used?
ISONIAZID FOR 9 MONTHS (EVIDENCE LEVEL C AND D):
Several therapeutic strategies have been proposed. Isoniazid is classically recommended as this drug in immunocompromised patients has proven to be effective (data derived from multiple studies in HIV patients) 59, 60, 61 . Isoniazid for a period of 9 months is the most commonly used regimen and has an estimated effi cacy of around 90%. This regimen is recommended by the American Thoracic Society (ATS) 62 and Canadian Tuberculosis Standards 63 , while the 6 months re gimen, in which effectiveness varies be-Position PaPer on tuberculosis screening in Patients with immune mediated inflammatory diseases candidates for biological theraPy tween 65-69%, is proposed by the National Institute for Health and Clinical Excellence (NICE) 64 .
TBNET recommends treatment with isoniazid for 9 to 12 months or isoniazid and rifampicin for 3 months (3HR) 19 . However, the later is associated with a lower efficacy (around 60%). Some studies indicate that 4 months of rifampicin (4R) are at least as effective as 3HR and this regime has the advantage of being better accepted by patients, having fewer adverse effects when compared with regimens based on isoniazid and is associated with a lower cost to the health system [65] [66] [67] [68] [69] . These are very relevant advantages but effectiveness remains uncertain, as this regimen has not yet been tested extensively in randomized trials.
In light of current knowledge, treatment with isoniazid for 9 months is the most consensual option 19, 60, 61 . One month is defined as the minimum LTBI treatment duration before starting biological drugs 19 . This recommendation is based on expert opinion.
evAluAtIon of the rIsk for toxIcIty due to ltbI treAtment
PATIENT EDUCATION, CLINICAL MONITORING, BASELINE AND MONTHLY LABORATORY TESTING OF LIVER ENZYMES (EVIDENCE LEVEL C AND D):
Given the high risk of TB in patients starting anti-TNF, the risk of age-related hepatotoxicity 70 should not prevent patients from receiving treatment for LTBI. In addi tion to liver toxicity, isoniazid is associated with toxicity to the nervous system 71 . Vitamin B6 reduces central and peripheral effects of isoniazid and should be given to individuals with a history of alcoholism, diabe tes, pregnant, postpartum, infants, malnourished, HIV-positive, people with active liver di sease, cancer or history of pre-existing peripheral neuropathy 72 .
In case of choosing rifampicin-based regimens, interactions with other drugs should be considered, since this drug is a potent inducer of CYP450 73 .
Besides patient education and clinical monitoring, baseline and monthly (or biweekly) laboratory testing of liver enzymes is recommended for people older than 35 years, chronic alcohol abusers, HIV-infected persons, females during pregnancy and within 3 months after delivery and for those with chronic liver disease or taking potentially hepatotoxic concomitant medications. Transient transaminase elevations are common and may reflect the process of hepatic adaptation. However, isoniazid and/or rifampicin should be withheld as recommended if the serum transaminase level is higher than three times the upper limit of normal in a symptomatic patient or five times the upper limit of normal in the absence of symptoms 61, 62 .
A change of the therapeutic regimen for a less hepatotoxic one (as 4R, at the expense of effectiveness) should be considered when serious hepatotoxicity is limiting LTBI treatment with isoniazid.
hoW should folloW up be performed?
Patients should be re-screened for LTBI if the previous screen had been negative and the patient had not started biologicals, to exclude possible infection in the meantime (in the absence of a known contact with a TB patient, the screen would be valuable for 6 months). In the event of contact with active TB, TB screening should be promptly performed and in the absence of disease and LTBI, chemoprophylaxis should be guaranteed 19 .
Annual testing is recommended for patients, who live, travel or work in environments where TB exposure is likely, while they continue treatment with biologic agents. Patients who tested positive for TST and IGRA should only be monitored for clinical signs of TB. summAry 1. All candidates for biologic therapy should be screened for TB. 2. TB screening procedures should include risk assessment, evaluation of TB signs and symptoms, chest radiography, TST and IGRA. 3. After exclusion of active TB, the presence of a positive TST (≥ 10 mm in immunocompetent or ≥ 5 mm in immunocompromised conditions) or positive IGRA indicates the possibility of LTBI and LTBI thera py should be offered. 4. The existence of an untreated or inadequately treated previous TB (determined by chest X-ray sequelae and/or clinical history) should be evaluated for active TB and, if that is excluded, LTBI treatment should be given. 5. In the event of a recent exposure to a TB patient, LTBI therapy should be offered, even in the pre sence of negative screening tests. 6. The recommended regimen for LTBI treatment is 9 months of isoniazid. 7. Annual testing is recommended while on biological treatment. 
